PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
October 5, 2025Journal of Alzheimer s Disease Reports6 citationsOpen Access

A surgical therapy for Alzheimer's disease with lymphaticovenular anastomosis

View Full Paper
XMXiwen MaFWFeiyun WangGWGuiqing Wang

Key Points

  • The average effectiveness rate of dcLVA surgery is 50%, highlighting its potential in treating Alzheimer's disease.
  • Clinical scores including CDR-SB demonstrated significant improvement in over half of the participants after the procedure.
  • Outcomes such as Aβ 42/40 ratio improvements suggest a biochemical response in most patients treated.
  • Minor adverse reactions were controlled effectively, indicating a positive safety profile of the surgical intervention.

Abstract

Background Deep cervical lymphaticovenular anastomosis (dcLVA) surgery is able to control aging-associated Alzheimer's disease in patients. However, the efficacy rate remains unknown. Objective This study is designed to test the surgery efficacy in the treatment of mild-to-moderate AD patients. Methods This is a single-center retrospective study of dcLVA treatment of mild-to-moderate AD for 3 months. A total of 41 patients received the surgery, in which lymph vessels and lymph nodes in the district III of cervical area were identified using indocyanine fluorescence dye. The afferent lymphatics of the obstructed lymph nodes were connected to the jugular vein to fix the lymphatic blockage under a fluorescent microscope. The efficacy rate was examined at 3-month post-surgery by clinical scores and biomarkers. Results Lymph flow obstruction was observed on both sides of cervical area in the AD patients. The obstruction was successfully resolved through the surgery, and AD progression was attenuated or even reversed in the patients according to improvement in the scales of MMSE, ADL, NPI, CDR-SB, and CGI-EI. The average effectiveness rate was 50% by the CDR-SB score improvement. The efficacy was higher with shorter disease duration but not influenced by age and APOE4 genotype. Aβ 42/40 ratio and p-tau181 were improved in more than 67% patients. There were 2 cases of mild adverse reactions that were controlled immediately by regular treatments. Conclusions The data demonstrate that dcLVA surgery is an effective and safe therapy for AD in mild-to-moderate patients with 50% efficacy rate as measured by improvement of the CDR-SB score.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Ma et al. (2025) studied this question.

synapsesocial.com/papers/68e24e65d6d66a53c24738d9https://doi.org/10.1177/25424823251384244
Ask AI
Helpful
Bookmark
Share
View Full Paper